The patient, a 39-year-old female with no family history of breast cancer, initially presented with a palpable left breast mass. A breast ultrasound showed an irregular, solid, macrolobulated mass measuring 21.0 x 19.8 x 15.7 mm in the left breast at the 12 o'clock position. Internal echotexture was heterogeneous, and microcalcifications and vascularity were seen in the mass. The location of the mass correlated to the palpable abnormality in the left breast, and the patient was categorized as BIRADS 4. On ultrasound, a lymph node measuring 12.4 x 12.8 x 7.8 mm was identified in the left axilla, and a lymph node measuring 11.2 x 10.7 x 8.7 mm was identified in the right axilla. Both lymph nodes had imaging characteristics of benign lesions.
lateral to the group of malignant calcifications, there was a second small clustered group of calcifications. In the right breast, no masses, significant calcifications, or other abnormalities were seen. Magnetic resonance imaging (MRI) of the breasts showed three masses in the upper inner left breast. These masses included a 2.1 x 1.7-cm mass with spiculated margins in the 11 o'clock position, 8 cm from the nipple, which corresponded to the known malignancy. The two additional masses included a 9 x 9-mm enhancing mass in the 10 o'clock position of the left breast, 7 cm from the nipple, and an adjacent 6 x 6-mm enhancing mass. The findings were suspicious for multifocal carcinoma.
The patient underwent a PET-CT scan for staging. Approximately 50 minutes after the intravenous administration of 13.0 mCi of FDG, whole-body PET-CT imaging was performed. The patient's blood glucose level was 86 mg/dl at the time of injection of FDG. Images demonstrated a dominant suspicious lobular soft-tissue mass in the upper inner quadrant of the left breast measuring 1.9 cm, with a maximum SUV of 9.9. Two additional suspicious foci were seen more inferolaterally, at least one of which had an anatomic correlate. These most likely corresponded to the abnormally enhancing foci on the recently performed MRI of the breasts and were consistent with multifocal involvement. Focal metabolic activity was noted corresponding to a benign-appearing, 1.4 x 0.9-cm, low-lying left axillary lymph node (maximum SUV 1.6), and a 1.2-cm lymph node deep to the pectoralis minor muscle with maximum SUV 2.3 (Figs. 1A, 1B, 1C ). These lymph nodes were suspicious for regional nodal metastases. There was no evidence of suspicious right axillary, mediastinal, or hilar lymph nodes, including locations in the internal mammary chains and in the mediastinal fat surrounding the heart.
The patient was scheduled for surgery, and pre-operative lymphoscintigraphy was performed. She received an intradermal, peri-areolar administration of 110 μCi of filtered Technetium 99m sulfur colloid in a volume of 0.1cc into the upper outer quadrant of the left breast, with emission and transmission imaging of the chest performed at 30 minutes. Lymphatics were visualized cranial to the injection site at 30 minutes; however, no discrete sentinel node was visualized at the time of imaging (Figs. 2A, 2B ).
Following lymphoscintigraphy, the Department of Nuclear Medicine was consulted because the surgeons could Figure 1B . 39-year-old woman with advanced breast cancer and nonvisualized sentinel node. FDG PET-CT axial image demonstrating the dominant suspicious lobular soft-tissue mass in the upper inner quadrant of the left breast, measuring 1.9 cm with a maximum SUV of 9.9. Focal metabolic activity was also noted corresponding to a benignappearing, 1.4 x 0.9-cm, low-lying left axillary lymph node with maximum SUV of 1.6. Figure 1C . 39-year-old woman with advanced breast cancer and nonvisualized sentinel node. FDG PET-CT axial image demonstrating a 1.2-cm lymph node deep to the pectoralis minor muscle with maximum SUV of 2.3. Figure 2A . 39-year-old woman with advanced breast cancer and nonvisualized sentinel node. Emission image obtained 30 minutes after intradermal, peri-areolar administration of 110 μCi of filtered Technetium 99m sulfur colloid in a volume of 0.1cc into the upper outer quadrant of the left breast demonstrates migration of tracer in the lymphatics cranial to the injection site; however, no sentinel node is visualized at the time of imaging.
not detect the sentinel node with the gamma probe in the operating room. The gamma detector was recalibrated, and surgeons were still unable to localize the sentinel node. Upon visual inspection and palpation of the lymph nodes, the surgeon was able to macroscopically detect lymph-node disease. The patient underwent a total left mastectomy, and pathology revealed one of the three sentinel-node specimens positive for metastatic carcinoma and six of the seven left axillary lymph nodes positive for metastatic carcinoma.
Discussion
We hypothesize that although there was migration of the Technetium 99m sulfur colloid by 30 minutes, the tracer did not reach the sentinel node by the time of surgery due to advanced disease that obstructed the flow of lymphatics. Such alteration in lymphatic flow as a result of advanced disease has been described previously with regard to melanoma, penile cancer, and breast cancer (1, 2). In breast cancer, previous studies have shown that an increased number of axillary lymph nodes with metastatic involvement is associated with nonvisualization of lymph nodes during lymphoscintigraphy (3, 4).
Although we believe that the cause of nonvisualization of the sentinel node on lymphoscintigraphy for this patient was extensive disease obstructing the lymphatic system, many other factors can affect visualization of lymph nodes during lymphoscintigraphy. It has previously been reported that age of the patient and tumor size may influence sentinel node detection rates (4, 5). Furthermore, the radiopharmaceutical used, the dose of the pharmaceutical, the particle size of the pharmaceutical, and the injection-toimaging time may all influence visualization of the sentinel node during lymphoscintigraphy (1). The site of pharmaceutical injection (whether intratumoral vs. extratumoral, intradermal vs. subdermal, or lateral vs. medial to a previous breast scar) can also affect visualization of the sentinel node during lymphoscintigraphy (6-12). Lastly, it is possible that a blue-dye injection in addition to Technetium 99m sulfur colloid and a gamma probe would have aided in detection of the sentinel node for this patient (13) (14) (15) (16) . Use of SPECT imaging in addition to planar imaging may have also provided additional information for sentinel-node localization in this patient (2, 17). Figure 2B . 39-year-old woman with advanced breast cancer and nonvisualized sentinel node. Transmission image obtained 30 minutes post-injection also demonstrates migration of tracer in the lymphatics cranial to the injection site; however, no sentinel node is visualized. 
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